Eli Lilly announces long-term data on Omvoh in Crohn’s disease

New long-term data from Eli Lilly (LLY) and Company showed Omvoh delivered durable efficacy through three years in adults with moderately to severely active Crohn’s disease. These data from the Phase 3 VIVID-2 open-label extension study were presented at the 21st Congress of the European Crohn’s and Colitis Organisation in Stockholm. Additional data presented from the Phase 3 VIVID-1 and LUCENT-3 clinical trials showed Omvoh-treated patients experienced minimal hospitalizations and surgeries across both major types of inflammatory bowel disease. Omvoh is the first and only IL-23p19 inhibitor to show strong and durable efficacy over four years in UC and three years in Crohn’s disease, with proven reduction of disease complications. “Too many people with inflammatory bowel disease never achieve lasting remission, leaving them vulnerable to cumulative damage from poorly controlled inflammation that can result in emergency hospitalizations or surgery,” said Adrienne Brown, EVP and president of Lilly Immunology. “Omvoh is redefining what durable disease control can look like, with long-term data showing patients treated with Omvoh stayed in remission and experienced fewer serious complications over three years, underscoring its potential to alter the course of the disease.” In VIVID-2, patients who achieved an endoscopic response at one year with Omvoh in the Phase 3 VIVID-1 clinical trial experienced long-term efficacy, with the majority remaining in clinical and corticosteroid-free remission and sustaining bowel urgency improvements through three years of continuous Omvoh treatment. These new long-term Crohn’s disease data also showed Omvoh-treated patients who achieved endoscopic response at one year experienced sustained improvement in inflammation, as measured by the continued decrease in inflammatory biomarkers up to three years.1 The long-term safety profile in patients with moderately to severely active Crohn’s disease was consistent with the known safety profile of Omvoh. Common adverse events reported from the end of year one through the end of year three included COVID-19, nasopharyngitis, and upper respiratory tract infection.